PT1135158E - Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica - Google Patents

Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica

Info

Publication number
PT1135158E
PT1135158E PT99963705T PT99963705T PT1135158E PT 1135158 E PT1135158 E PT 1135158E PT 99963705 T PT99963705 T PT 99963705T PT 99963705 T PT99963705 T PT 99963705T PT 1135158 E PT1135158 E PT 1135158E
Authority
PT
Portugal
Prior art keywords
immunogenic polypeptides
methods
mammal
ige
nucleic acid
Prior art date
Application number
PT99963705T
Other languages
English (en)
Inventor
Lars T Hellman
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Publication of PT1135158E publication Critical patent/PT1135158E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT99963705T 1998-11-02 1999-10-21 Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica PT1135158E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
PT1135158E true PT1135158E (pt) 2006-05-31

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99963705T PT1135158E (pt) 1998-11-02 1999-10-21 Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica

Country Status (18)

Country Link
US (3) US6913749B2 (pt)
EP (1) EP1135158B1 (pt)
JP (2) JP4205861B2 (pt)
KR (1) KR100559918B1 (pt)
AT (1) ATE314087T1 (pt)
AU (1) AU771889B2 (pt)
CA (1) CA2348756A1 (pt)
DE (1) DE69929240T2 (pt)
DK (1) DK1135158T3 (pt)
ES (1) ES2255325T3 (pt)
HK (1) HK1042844A1 (pt)
HU (1) HUP0105392A3 (pt)
IL (1) IL142582A0 (pt)
NO (1) NO20012135L (pt)
NZ (1) NZ511079A (pt)
PL (1) PL348611A1 (pt)
PT (1) PT1135158E (pt)
WO (1) WO2000025722A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP1967205B1 (en) * 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
US20020172673A1 (en) * 2000-09-06 2002-11-21 Pharmexa A/S Method for down-regulating IgE
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
CA2698079C (en) 2001-02-20 2015-01-13 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
WO2002092773A2 (en) 2001-05-15 2002-11-21 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
CA2486464A1 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
JP2006510588A (ja) * 2002-09-05 2006-03-30 レジステンシア ファーマシューティカルズ アーベー アレルギーワクチン
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
ES2622562T3 (es) 2008-12-09 2017-07-06 Pfizer Vaccines Llc Vacuna de péptido CH3 de IgE
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
RU2018130010A (ru) 2016-02-16 2020-03-17 Регенерон Фармасьютикалз, Инк. Животные, отличные от человека, имеющие мутантный ген кинурениназы

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
JP2724625B2 (ja) 1987-12-31 1998-03-09 タノックス・バイオシステムズ・インコーポレーテッド ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
WO1991011456A1 (en) 1990-01-23 1991-08-08 Tanox Biosystems, Inc. EXTRACELLULAR SEGMENTS OF HUMAN ε IMMUNOGLOBULIN ANCHORING PEPTIDES AND ANTIBODIES SPECIFIC THEREFOR
DE69112225T2 (de) 1990-05-25 1996-01-04 Peptide Therapeutics Ltd Immunodiagnostische probe für gelenkrheumatismus.
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
EP0561960A1 (en) * 1990-12-13 1993-09-29 Immunex Corporation Leukemia inhibitory factor receptors
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
WO1994005698A1 (en) 1992-09-01 1994-03-17 United Nations Industrial Development Organization Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
JPH09510975A (ja) 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド アレルギー治療用合成ペプチドベース免疫原
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
EP0787150A1 (en) 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
GB9422294D0 (en) 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
ES2230566T3 (es) 1995-07-17 2005-05-01 Medivir Uk Ltd Inhibidores de la cisteina proteasa para el tratamiento de enfermedades alergicas mediadas por la inmunoglobulina e (ige).
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
RU2193413C2 (ru) 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
AU730477B2 (en) 1996-08-05 2001-03-08 President And Fellows Of Harvard College MHC binding peptide oligomers and methods of use
HUP0001930A3 (en) 1997-04-15 2001-10-29 Pharmexa As Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
MXPA01003503A (es) 1998-10-05 2005-01-14 Pharmexa As Nuevos metodos terapeuticos de vacunacion.
IL143441A0 (en) 1998-11-30 2002-04-21 Cytos Biotechnology Ag Non-naturally occuring antigen arrays and processes for the preparation thereof
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
AU777952B2 (en) 1999-04-23 2004-11-04 Pharmexa A/S Method for down-regulating IL5 activity
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
US20020172673A1 (en) 2000-09-06 2002-11-21 Pharmexa A/S Method for down-regulating IgE
WO2002102320A2 (en) 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma

Also Published As

Publication number Publication date
NZ511079A (en) 2003-08-29
DE69929240T2 (de) 2006-08-31
US20030031663A1 (en) 2003-02-13
HUP0105392A3 (en) 2008-04-28
JP4188353B2 (ja) 2008-11-26
NO20012135L (no) 2001-06-25
WO2000025722A3 (en) 2000-10-12
US20040076625A1 (en) 2004-04-22
DK1135158T3 (da) 2006-05-15
AU2008100A (en) 2000-05-22
WO2000025722A2 (en) 2000-05-11
US20010038843A1 (en) 2001-11-08
DE69929240D1 (de) 2006-02-02
HK1042844A1 (en) 2002-08-30
US7459158B2 (en) 2008-12-02
KR20010089364A (ko) 2001-10-06
KR100559918B1 (ko) 2006-03-13
EP1135158B1 (en) 2005-12-28
CA2348756A1 (en) 2000-05-11
ATE314087T1 (de) 2006-01-15
JP2006068015A (ja) 2006-03-16
AU771889B2 (en) 2004-04-08
US6913749B2 (en) 2005-07-05
IL142582A0 (en) 2002-03-10
HUP0105392A2 (hu) 2002-04-29
ES2255325T3 (es) 2006-06-16
JP4205861B2 (ja) 2009-01-07
NO20012135D0 (no) 2001-04-30
JP2002531064A (ja) 2002-09-24
EP1135158A2 (en) 2001-09-26
PL348611A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
PT1135158E (pt) Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica
NO346167B1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
CR9236A (es) Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
NO20052714D0 (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
WO2004000238A3 (en) Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
Lou et al. Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses